Nakagaito Masaki, Imamura Teruhiko, Ushijima Ryuichi, Nakamura Makiko, Kinugawa Koichiro
Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
J Clin Med. 2024 May 29;13(11):3196. doi: 10.3390/jcm13113196.
: The clinical impact of the withdrawal of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on all-cause readmission in patients with heart failure remains unknown. : We enrolled a total of 212 consecutive patients who were hospitalized for heart failure and received SGLT2i during their index hospitalization between February 2016 and July 2022. Of these patients, 51 terminated SGLT2i during or after their index hospitalization. We evaluated the prognostic impact of the withdrawal of SGLT2i on the primary outcome, which was defined as the all-cause readmission rate/times. : Over a median of 23.2 months, all-cause readmission occurred in 38 out of 51 patients (74.5%) withdrawn from SGLT2i and 93 out of 161 patients (57.8%) with continuation of SGLT2i ( = 0.099). The incidence of all-cause readmissions per year was 0.97 [0-1.50] in patients withdrawn from SGLT2i and 0.50 [0-1.03] in patients with continuation of SGLT2i ( = 0.030). There was no significant difference in total medical costs (62,906 [502-187,246] versus 29,236 [7920-180,305] JPY per month, = 0.866) between both patient groups. : Termination of SGLT2i may be associated with incremental all-cause readmission and no benefit in reducing total medical costs.
钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）停药对心力衰竭患者全因再入院的临床影响尚不清楚。我们共纳入了212例连续的心力衰竭住院患者，这些患者在2016年2月至2022年7月的首次住院期间接受了SGLT2i治疗。在这些患者中，51例在首次住院期间或之后停用了SGLT2i。我们评估了停用SGLT2i对主要结局的预后影响，主要结局定义为全因再入院率/次数。在中位23.2个月的时间里，停用SGLT2i的51例患者中有38例（74.5%）发生了全因再入院，继续使用SGLT2i的161例患者中有93例（57.8%）发生了全因再入院（P = 0.099）。停用SGLT2i的患者每年全因再入院发生率为0.97[0 - 1.50]，继续使用SGLT2i的患者为0.50[0 - 1.03]（P = 0.030）。两组患者的每月总医疗费用无显著差异（分别为62,906[502 - 187,246]日元和29,236[7920 - 180,305]日元，P = 0.866）。停用SGLT2i可能与全因再入院增加有关，且在降低总医疗费用方面无益处。
